UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

~~February 27~~April 3, 2024

KINNATE BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39743		82-4566526
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS ~~Employer~~EmployerIdentification ~~Identification~~ No.)

Address Not Applicable1

(Address, including zip code, of registrant’s principal executive offices)

(858) 299-4699

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

KNTE

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Kinnate Biopharma Inc. (the “Registrant”) terminated its lease agreements for office space. Accordingly, the Registrant does not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to the Registrant’s principal executive offices may be sent to Kinnate Biopharma Inc., 800 West El Camino Real, Suite 180, Mountain View, CA 94040, and should not be directed to the Registrant’s agent for service of process at The Corporation Trust Company, 1209 Orange Street, Wilmington, DE 19801, as previously listed.

Item 1.01 Entry into a Material Definitive Agreement.

Asset Purchase Agreement

On February 27, 2024, Kinnate Biopharma Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) by and among the Company and Pierre Fabre Médicament, SAS (“Pierre Fabre”), pursuant to which it sold the global rights to its investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets to Pierre Fabre, subject to the terms and conditions of the Purchase Agreement.

Pursuant to the terms of the Purchase Agreement, Pierre Fabre purchased exarafenib and other pan-RAF assets and will assume 100% of the ongoing program and costs associated with these assets. The Company will receive a total consideration of up to $31.0 million, consisting of $500,000 at closing, and an additional $30.5 million contingent upon the earlier of (i) the dosing of the first patient in the first pivotal trial for exarafenib or any other acquired asset, (ii) the application for accelerated approval pursuant to the U.S. Food and Drug Administration’s Accelerated Approval Program for exarafenib or any other acquired asset or (iii) the submission of a marketing application for regulatory approval for exarafenib or any other acquired asset. In addition, Pierre Fabre will assume up to $5.0 million of trade payables for the transferred assets. The transaction is not subject to closing conditions and closed upon signing.

As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on February 16, 2024, in connection with the Company’s transaction with XOMA Corporation (“XOMA”), the Company’s stockholders will receive 100% of the net proceeds (after deducting appliable costs, expenses, taxes or other deductions pursuant to the Contingent Value Rights Agreement to be entered into in connection with the proposed transaction with XOMA (the “CVR Agreement”)) payable from the $30.5 million contingent payment, assuming the closing of the proposed transaction with XOMA occurs and such proceeds are received within five years from the closing date thereof, pursuant to the CVR Agreement. There will be no net proceeds from the $500,000 closing payment, as such payment will only cover transaction expenses.

The foregoing description of the Purchase Agreement is qualified in its entirety by reference to the full text of the Purchase Agreement, which is filed hereto as Exhibit 2.1 and incorporated herein by reference.

Item 2.01

Completion of Acquisition or Disposition of Assets.

~~The~~As ~~disclosure~~previously ~~set~~disclosed ~~forth~~by ~~under~~Kinnate ~~Item~~Biopharma Inc. (the “Company” or “Kinnate”) in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on February 16, 2024, the Company entered into an Agreement and Plan of Merger, dated as of February 16, 2024 (the “Merger Agreement”), with XOMA Corporation, a Delaware corporation (“Parent”), and XRA 1 Corp.01, isa ~~incorporated~~Delaware ~~herein~~corporation byand ~~reference~~a wholly owned subsidiary of Parent (“Merger Sub”).

~~Item~~Pursuant 7to the Merger Agreement, and upon the terms and subject to the conditions thereof, on April 3, 2024, Merger Sub completed a tender offer to purchase all of the Company’s outstanding shares of common stock, par value $0.010001 ~~Regulation~~per FDshare ~~Disclosure~~(the “Shares”), in exchange for (i) $2.5879 in cash per Share (the “Cash Amount”), plus (ii) one non-transferable contractual contingent value right per Share (each, a “CVR” and each CVR together with the Cash Amount, the “Offer Price”), which CVR represents the right to receive potential payments pursuant to the terms and subject to the conditions of the contingent value rights agreement (the “CVR Agreement”), dated April 3, 2024, by and among Parent, Merger Sub, Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania limited liability company, and Fortis Advisors LLC, a Delaware limited liability company, all subject to and in accordance with the terms and conditions set forth in the Offer to Purchase, dated March 4, 2024 (as amended and restated on March 19, 2024, the “Offer to Purchase”), and in the related Letter of Transmittal (as amended or supplemented from time to time, the “Letter of Transmittal,” which, together with the Offer to Purchase, as each may have been amended or supplemented, constituted the “Offer”).

OnThe ~~March~~foregoing 1,description ~~2024,~~of the ~~Company~~CVR ~~issued~~Agreement adoes ~~press~~not ~~release~~purport ~~announcing~~to be complete and is qualified in its entirety by reference to the ~~signing~~full text of the ~~Purchase~~CVR Agreement, a copy of which is ~~attached~~filed ~~hereto~~ as Exhibit 992.1 2 to Parent’s Current Report on Form 8-K filed on April 3, 2024 and is incorporated herein by reference.

The ~~information~~Offer ~~contained~~expired inat ~~this~~one ~~Item~~minute 7after 11:59 p.01m., ~~including~~Eastern ~~Exhibit~~time, ~~99.1~~on ~~attached~~Tuesday, ~~hereto~~April 2, is2024. ~~being~~According ~~furnished~~to ~~and~~Broadridge ~~shall~~Corporate ~~not~~Issuer beSolutions, ~~deemed “filed”~~LLC, ~~for~~the ~~purposes~~depositary ofand ~~Section~~paying 18agent offor the ~~Securities~~Offer, ~~Exchange~~a ~~Act~~total of ~~1934~~38,258,681 asShares ~~amended~~were ~~(the~~validly ~~“Exchange~~tendered, ~~Act”)~~and not validly withdrawn, orrepresenting ~~otherwise~~approximately ~~subject~~81% toof the ~~liabilities~~outstanding Shares. The number of ~~that~~Shares ~~section,~~tendered ~~nor~~satisfied ~~shall~~the itMinimum beTender ~~deemed~~Condition ~~incorporated~~(as bydefined ~~reference~~in ~~into~~the ~~any~~Merger ~~filing~~Agreement). ~~under~~All other conditions to the ~~Securities Act~~ ofOffer ~~1933,~~were assatisfied ~~amended,~~and orMerger ~~the Exchange~~Sub ~~Act,~~accepted ~~except~~for aspayment ~~expressly~~all ~~set~~Shares ~~forth~~validly bytendered ~~specific~~(and ~~reference~~not invalidly ~~such~~withdrawn) ~~filing~~prior to the expiration of the Offer.

~~Important~~Following ~~Additional~~the ~~Information~~consummation of the Offer, the remaining conditions to the Merger set forth in the Merger Agreement were satisfied, and ~~Where~~on April 3, 2024 (the “Closing Date”), Merger Sub merged with and into the Company (the “Merger”), the separate corporate existence of Merger Sub ceased and the Company continued as the surviving corporation in the Merger (the “Surviving Corporation”) and a wholly owned subsidiary of Parent. The Merger was completed pursuant to ~~Find~~Section 251(h) Itof the General Corporation Law of the State of Delaware, as amended (the “DGCL”), with no stockholder vote required. At the effective time of the Merger (the “Effective Time”), each outstanding Share (other than (i) Shares held in the treasury of the Company immediately prior to the Effective Time, which will be canceled without any conversion thereof and no consideration will be delivered in exchange therefor, and (ii) any Shares held by stockholders or owned by beneficial owners who are entitled to demand, and have properly demanded, appraisal of such Shares in accordance with the DGCL and have neither failed to perfect nor effectively withdrawn or lost such rights prior to the Effective Time) was converted automatically into the right to receive the Offer Price from Merger Sub.

InPursuant ~~connection with the proposed acquisition of the Company, XOMA or its affiliates will commence a tender offer for all of the outstanding shares of the Company (the “Offer”) pursuant~~ to the terms of ~~an Agreement and Plan of Merger, dated as of February 16, 2024 (~~the “Merger Agreement”), byimmediately ~~and~~prior ~~among~~to the ~~Company,~~Effective ~~XOMA~~Time, ~~and~~each ~~XRA~~option 1granted ~~Corp., a~~to ~~Delaware~~purchase ~~corporation~~Shares ~~and~~(each, a ~~wholly owned~~“Kinnate ~~subsidiary~~Option”) ofthat ~~XOMA.~~was ~~The~~then ~~Offer~~outstanding ~~has~~but not ~~yet~~then ~~commenced,~~vested ~~and~~or ~~this~~exercisable ~~Current~~was ~~Report~~immediately onvested ~~Form~~and ~~8-K~~exercisable isin ~~neither~~full. aAfter ~~recommendation,~~giving ~~nor~~effect ~~an offer~~ to ~~purchase~~such ~~nor~~accelerated avesting, ~~solicitation~~at ~~of an offer to sell any shares of~~ the ~~common~~Effective ~~stock of the Company or any other securities. On the commencement date of the Offer~~Time, aeach ~~tender~~Kinnate ~~offer~~Option ~~statement~~that onwas ~~Schedule~~then ~~TO,~~outstanding ~~including~~with ~~an offer to purchase,~~ a ~~letter~~per ofshare ~~transmittal~~exercise ~~and~~price ~~related~~that ~~documents,~~was ~~will~~less bethan ~~filed with~~ the ~~SEC~~Cash byAmount ~~XOMA~~(an ~~and its acquisition subsidiary, and a Solicitation/Recommendation Statement on Schedule 14D~~“In-9the-Money ~~will~~Option”) bewas ~~filed~~canceled ~~with~~in ~~the~~exchange ~~SEC~~for by the ~~Company.~~right ~~The Offer~~ to ~~purchase~~receive ~~the~~(i) an ~~outstanding~~amount ~~shares~~in ofcash ~~Common~~without ~~Stock~~interest, ~~will~~less ~~only~~any beapplicable ~~made~~tax ~~pursuant~~withholding, toequal ~~the offer~~ to ~~purchase,~~ the ~~letter~~product ofobtained ~~transmittal~~by ~~and~~multiplying ~~related documents~~(x) the ~~filed~~excess ~~as a part~~ of the ~~Schedule~~Cash ~~TO.~~Amount ~~INVESTORS~~over ~~AND~~the ~~SECURITY~~per ~~HOLDERS~~share ~~ARE~~exercise ~~URGED~~price TOof ~~READ~~such ~~THE~~In-the-Money ~~TENDER~~Option ~~OFFER~~by ~~MATERIALS~~ (~~INCLUDING~~y) the ~~THE~~number ~~OFFER~~of ~~TO PURCHASE,~~Shares Aunderlying ~~LETTER~~such OFIn-the-Money ~~TRANSMITTAL~~Option ~~AND~~and ~~RELATED DOCUMENTS~~(ii) one ~~AND~~CVR ~~THE~~for ~~SOLICITATION/RECOMMENDATION~~each ~~STATEMENT~~Share ONunderlying ~~SCHEDULE~~such ~~14D~~In-9the-Money ~~REGARDING~~Option. ~~THE~~At ~~OFFER,~~the ASEffective ~~THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME~~Time, ~~WHEN~~each ~~THEY~~Kinnate ~~BECOME~~Option ~~AVAILABLE~~that ~~BECAUSE~~was ~~THEY~~then ~~WILL CONTAIN~~outstanding ~~IMPORTANT~~with ~~INFORMATION~~a ~~THAT~~per ~~INVESTORS~~share ~~AND~~exercise ~~SECURITY~~price ~~HOLDERS~~that ~~SHOULD~~was ~~CONSIDER~~equal ~~BEFORE~~to ~~MAKING~~or ~~ANY~~greater ~~DECISION~~than ~~REGARDING~~the ~~TENDERING~~Cash ~~THEIR~~Amount ~~SHARES,~~(an ~~INCLUDING THE TERMS AND CONDITIONS OF THE OFFER. Investors and security holders may obtain a free copy~~ “Out-of-the-Money ~~these statements (when available~~Option”) ~~and~~was ~~other~~canceled ~~documents~~in ~~filed~~exchange ~~with~~for the ~~SEC~~right atto ~~the~~receive ~~website~~one ~~maintained~~CVR byfor ~~the~~each ~~SEC~~Share atunderlying ~~www.sec.gov or by directing~~ such ~~requests to~~ Out-of-the-Money ~~information~~Option; ~~agent~~provided ~~for~~that ~~the~~each ~~Offer,~~such ~~which~~CVR will beprovide ~~named~~for inpayment ~~the~~only ~~tender~~after ~~offer statement.~~amounts ~~Investors~~otherwise ~~and~~payable ~~security~~under ~~holders~~such ~~may~~CVR ~~also~~exceed ~~obtain,~~a atthreshold noequal ~~charge, the documents filed or furnished~~ to the ~~SEC~~excess byof the ~~Company~~per ~~under~~share ~~the~~exercise ~~“SEC~~price ~~Filings”~~of ~~subsection~~such Out-of -the-Money ~~“Financial~~Option ~~Information”~~over ~~section of~~ the ~~Company’s~~Cash ~~website at https://investors~~Amount.~~kinnate.com/.~~

~~Cautionary~~Immediately ~~Note~~prior ~~Regarding~~to ~~Forward~~the time at which Purchaser first irrevocably accepted for purchase the Shares tendered in the Offer (the “Offer Closing Time”), each then-~~Looking~~outstanding ~~Statements~~restricted stock unit representing a contingent right to receive one Share upon vesting (each, a “Kinnate RSU”) that was not then vested was immediately vested in full. After giving effect to such accelerated vesting, at the Effective Time, each outstanding Kinnate RSU was canceled in exchange for the right to receive (i) an amount in cash without interest, less any applicable tax withholding, equal to the Cash Amount and (ii) one CVR.

~~This~~The ~~Current~~foregoing ~~Report~~description on Form 8-K contains forward-looking statements, including, but not limited to, statements regarding the consideration to be received by the Company under the Purchase Agreement; the liabilities to be assumed by Pierre Fabre under the Purchase Agreement; the Company’s beliefs and expectations and statements about the CVR Agreement; and the potential payment of ~~proceeds to~~ the ~~Company’s~~Merger ~~stockholders, if any, pursuant to the Purchase~~ Agreement and ~~CVR Agreement, including with respect to any net proceeds or contingent payments related to exarafenib or any other pan-RAF asset under~~ the ~~Purchase Agreement.~~transactions ~~These~~contemplated ~~statements~~thereby ~~may~~does ~~be identified by their use of forward-looking terminology including, but~~ not ~~limited~~purport to, ~~“anticipate,”~~be ~~“believe,”~~complete “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” and ~~“would,”~~is ~~and~~qualified ~~similar~~in ~~words~~its ~~expressions~~entirety are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance and involve risks and uncertainties that could cause actual results to differ materially from those projected, expressed or implied by ~~such~~reference ~~forward-looking statements. These risks and uncertainties include, but are not limited~~ to: the ~~possibility~~full ~~that~~text ~~various closing~~of ~~conditions set forth in~~ the Merger Agreement ~~may~~attached ~~not be satisfied or waived, including uncertainties~~ as toExhibit ~~the~~2.1 ~~percentage of the Company’s stockholders tendering their shares in the Offer; the possibility that competing offers will be made; the Company’s ability~~ to ~~retain key personnel;~~ the ~~risk~~Current ~~that~~Report ~~the~~on ~~Offer,~~Form 8-K filed ~~the merger of Merger Sub with and into the Company and the other transactions contemplated~~ by the ~~Merger Agreement and the CVR Agreement (collectively, the “Transactions”) may not be completed in a timely manner, or at all, which may adversely affect the~~ Company’s ~~business~~on and the price of its common stock; significant costs associated with the proposed Transactions; the risk that any stockholder litigation in connection with the Transactions may result in significant costs of defenseFebruary 16, ~~indemnification~~2024 and ~~liability;~~incorporated the risk that activities related to the CVR Agreement may not result in any value to the Company’s stockholders; and other risks and uncertainties discussed in the Company’s most recent annual and quarterly reports filed with the SEC as well as in the Company’s subsequent filings with the SEC. As a result of such risks and uncertainties, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by ~~the forward-looking statements contained herein~~reference. ~~There can be no assurance that the proposed Transactions will in fact be consummated. The Company cautions investors not to unduly rely on any forward-looking statements.~~

~~The~~Item ~~forward-looking~~3.01 ~~statements~~Completion ~~contained in this Current Report on Form 8-K are made as~~ of ~~the~~Acquisition ~~date~~or ~~hereof,~~Disposition ~~and the Company undertakes no obligation to update any forward-looking statements, whether as a result~~ of ~~future events, new information or otherwise, except as expressly required by law~~Assets. ~~All forward-looking statements in this document are qualified in their entirety by this cautionary statement.~~

The information set forth under Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.01.

In connection with the consummation of the Offer and the Merger, the Company (i) notified the Nasdaq Global Select Market LLC (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq (A) suspend trading of the Shares effective before the opening of trading on April 3, 2024 and (B) file with the SEC a Notification of Removal from Listing and/or Registration on Form 25 to effect the delisting of all Shares from Nasdaq and the deregistration of such Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In addition, the Surviving Corporation intends to file a Certification and Notice of Termination of Registration on Form 15 with the SEC requesting the termination of registration of the Shares under Section 12(g) of the Exchange Act and the suspension of reporting obligations under Section 13 and 15(d) of the Exchange Act with respect to the Shares.

Item 3.03

Material Modification to Rights of Security Holders.

The information set forth under Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

Item 5.01

Changes in Control of Registrant.

The information set forth under Items 2.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.

As a result of the consummation of the Offer and the Merger, there was a change in control of the Company, and the Company became a wholly owned subsidiary of Parent.

Item 5.02

Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Dean J. Mitchell, Nima Farzan, Jill DeSimone, Melissa Epperly, Keith Flaherty, Carl Gordon, Michael Rome, Helen Sabzevari, Laurie Smaldone Alsup and James Tananbaum resigned from the board of directors of the Company. Additionally, at the Effective Time, each of Nima Farzan, Neha Krishnamohan and Mark Meltz resigned as officers of the Company. These resignations were tendered in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company’s operations, policies or practices.

Following the Merger and pursuant to the terms of the Merger Agreement, at the Effective Time, the director and officer of Merger Sub immediately prior to the Effective Time became the director and officer of the Surviving Corporation. The sole director of Merger Sub immediately prior to the Effective Time was Owen Hughes. The sole officer of Merger Sub immediately prior to the Effective Time was Owen Hughes, serving as President, Treasurer and Secretary.

Information regarding the new director and officer of the Surviving Corporation has been previously disclosed in Schedule A to the Offer to Purchase, which is incorporated herein by reference.

Item 5.03

Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Pursuant to the terms of the Merger Agreement, immediately following the Effective Time, (i) the Surviving Corporation’s certificate of incorporation was amended and restated in its entirety, as set forth on Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference, and (ii) the bylaws of Merger Sub as in effect immediately prior to the Effective Time became the bylaws of the Surviving Corporation, as set forth on Exhibit 3.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 8.01

Other Events.

Termination of Sales Agreement

Effective as of the Closing Date, the Company exercised its right to terminate that certain Sales Agreement, dated January 3, 2022, by and between the Company and Leerink Partners LLC (f/k/a SVB Leerink LLC), as sales agent.

Closing Press Release

On April 3, 2024, Parent issued a press release announcing the expiration and results of the Offer and the consummation of the Merger. The full text of the press release issued by Parent is attached as Exhibit (a)(5)(D) to the Schedule TO-T/A filed by Parent and Merger Sub on April 3, 2024.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
ExhibitNo.		Description
2.1+	~~Asset Purchase Agreement, dated February 27, 2024, by and among Kinnate Biopharma Inc. and Pierre Fabre Médicament, SAS.~~	Agreement and Plan of Merger, dated February 16, 2024, by and among the Company, Parent and Merger Sub (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on February 16, 2024).
99.1	Press Release dated March 1, 2024.
2.2+		Contingent Value Rights Agreement, dated April 3, 2024, by and among Parent, Merger Sub, Broadridge Corporate Issuer Solutions, LLC and Fortis Advisors LLC (incorporated herein by reference to Exhibit 2.2 to Parent’s Current Report on Form 8-K filed on April 3, 2024).
104	Cover page interactive data file (embedded within the inline XBRL document).
3.1*		Seventh Amended and Restated Certificate of Incorporation of the Company.
3.2*		Amended and Restated Bylaws of the Company.
99.1		Press Release of Parent issued on April 3, 2024 (incorporated herein by reference to Exhibit (a)(5)(D) to the Schedule TO-T/A filed by Parent and Merger Sub on April 3, 2024).
104		Cover page interactive data file (embedded within the inline XBRL document).

Certain exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted schedules and annexes upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any annexes or schedules so furnished.

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KINNATE BIOPHARMA INC.
Date: March 1, 2024	By:	/s/ Nima Farzan
		Nima Farzan Chief Executive Officer and President


KINNATE BIOPHARMA INC.

By:		/s/ Nima Farzan
		Nima Farzan Chief Executive Officer and President

Date: April 3, 2024

Filing Compare · Kinnate Biopharma Inc.